Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study has been completed.
Study NCT00143065 Information provided by Ohio State University Comprehensive Cancer Center
First Received on August 31, 2005. Last Updated on October 20, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma, Small Lymphocytic
Lymphocytic Leukemia, Chronic
Additional conditions recognized in this trial
Chronic Disease
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Lymphoma
More general conditions related to this trial
Disease Attributes
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Interventions listed in this trial
Fludarabine
Rituximab
Alemtuzumab
Additional drug interventions recognized in this trial
Antibodies, Neoplasm
Campath 1G
Fludarabine monophosphate
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Ohio State University Comprehensive Cancer Center
Back to top of Main Content
